Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information. Issue 7 (10th May 2021)

• Record Type: Journal Article
• Authors: Zhang, Yuzi; Kutner, Michael; Chen, Zhengjia
• Is Part Of: Biometrical journal. Volume 63:Issue 7(2021)
• Page Start: 1476
• Page End: 1492
• Publication Date: 2021-05-10
• Subjects: cancer phase I clinical trial -- drug combination -- escalation with overdose control -- maximum tolerated dose curve -- quasi‐continuous toxicity response; Biometry -- Periodicals; Medical statistics -- Periodicals; 570.15195
• DOI: 10.1002/bimj.202000142
• Languages: English
• ISSNs: 0323-3847

Abstract

Abstract: The combined treatments with multiple drugs are very common in the contemporary medicine, especially for medical oncology. Therefore, we developed a Bayesian adaptive Phase I clinical trial design entitled escalation with overdoing control using normalized equivalent toxicity score for estimating maximum tolerated dose (MTD) contour of two drug combination (EWOC‐NETS‐COM) used for oncology trials. The normalized equivalent toxicity score (NETS) as the primary endpoint of clinical trial is assumed to follow quasi‐Bernoulli distribution and treated as quasi‐continuous random variable in the logistic linear regression model which is used to describe the relationship between the doses of the two agents and the toxicity response. Four parameters in the dose–toxicity model were re‐parameterized to parameters with explicit clinical meanings to describe the association between NETS and doses of two agents. Noninformative priors were used and Markov chain Monte Carlo was employed to update the posteriors of the four parameters in dose–toxicity model. Extensive simulations were conducted to evaluate the safety, trial efficiency, and MTD estimation accuracy of EWOC‐NETS‐COM under different scenarios, using the EWOC as reference. The results demonstrated that EWOC‐NETS‐COM not only efficiently estimates MTD contour of multiple drugs but also provides better trial efficiency by fully utilizing all toxicity information.